New pill combo aims to tackle Hard-to-Treat colorectal cancer

NCT ID NCT07391566

Not yet recruiting Disease control Sponsor: Luye Pharma Group Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a new oral drug, LPM6690176, added to standard chemotherapy and bevacizumab for people with a specific type of advanced colorectal cancer (RAS mutation). The first part finds the safest dose, and the second part compares the new combo against standard treatment alone. About 99 adults who have not had prior therapy for metastatic disease will participate.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LPM6690176 capsules combined with chemotherapy (FOLFIRI) and bevacizumab
What this could lead to: If successful, this could offer a new first-line treatment option for people with RAS-mutant metastatic colorectal cancer, potentially improving tumor shrinkage and delaying progression.
What could go wrong: This is an early-phase trial (Phase 1b/2) with only 99 participants, so safety and effectiveness are not yet proven. The drug combination may cause significant side effects, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (MCRC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLORECTAL CANCER (MCRC)

Contacts and locations

Locations

Beijing Cancer Hospital

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.